CDT Equity (CDT) Non-Current Deferred Revenue (2022 - 2023)
CDT Equity's Non-Current Deffered Revenue was $2.67 million in Q3 2023, down 63.6% from $7.32 million a year earlier.
Powered by 
Analysis
CDT Equity (CDT) Non-Current Deferred Revenue (2022 - 2023) Analysis & Trends
At the end of FY2022, Non-Current Deffered Revenue at CDT Equity came in at $4.08 million.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn |
| 10 | CDT Equity | 426.40 | -6.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 2.67 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Sep 30, 2022 | 7.32 Mn |
| Jun 30, 2022 | 4.63 Mn |
API Access
CDT Equity Non-Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=CDT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "non-current-deffered-revenue", "ticker": "CDT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=CDT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();